An Assessment of Patient Position and Intravesical BCG Dwell Time

What this Trial Is About

Researchers are evaluating whether the position of a patient during intravesical bacillus Calmette Guerin (BCG) treatment affects how long the BCG medication stays in the bladder, called dwell time. This is important for treating intermediate and high risk non-muscle invasive bladder cancer (NMIBC). The study also explores the use of a fitness tracker to monitor patient activity and vital signs during treatment to better understand factors that may influence treatment retention and effectiveness. Participants receive standard BCG therapy once a week for three weeks, with different post-treatment positioning for each session. During the first treatment, patients follow usual instructions to hold the BCG in their bladder for two hours without activity restrictions. In the second treatment, patients lie down as long as possible for up to two hours while holding the BCG. The third treatment requires patients to remain sitting for up to two hours. Throughout the study, participants wear a Fitbit to track activity and vital signs. During the trial, participants will be monitored for how long they retain the BCG medication, compliance with activity instructions, and adherence to wearing the fitness tracker. Researchers will collect data through vital sign monitoring, patient surveys, and electronic health record reviews. The main outcome measured is the BCG dwell time up to two hours, assessed over five weeks. Participants will be discharged immediately after treatment, with no disease progression or unacceptable toxicity expected during the study period.

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer